LexDanaLexDanabeta
Inventor

Atsushi OYAGI

Inventor
JP

Overview

2→
Patents
2025–2026
Patent span
Human necessities
Primary field (CPC A)

Patents· 2 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes20%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms20%
G01NInvestigating or analysing materials by determining their chemical or physical properties20%
C07KPeptides10%
C12NMicroorganisms or enzymes10%
PatentTitleYear
12,571,799Biomarkers for determining the efficacy of immune checkpoint inhibitors202612,240,903Biomarkers for determining the effectiveness of immune checkpoint inhibitors2025

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2025–2026Patents assigned to NAT CANCER CT (2)· patent assignee history
2025–2026Patents assigned to ONO PHARMACEUTICAL CO (2)· patent assignee history
2025–2026Based in JP· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
NAT CANCER CT22025–2026
ONO PHARMACEUTICAL CO22025–2026
Locations
LocationPatentsSpan
JP22025–2026